Glaxosmithkline Pharmaceuticals Ltd (GLAXO) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 500660 | NSE: GLAXO | Pharmaceuticals & Drugs | Mid Cap

Glaxosmithkline Phar Share Price

2,568 58.70 2.34%
as on 05-Dec'25 09:52

Glaxosmithkline Pharmaceuticals Ltd (GLAXO) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 500660 | NSE: GLAXO | Pharmaceuticals & Drugs | Mid Cap

DeciZen - make an informed investing decision on Glaxosmithkline Phar

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Glaxosmithkline Pharmaceuticals stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
44.50
Market Cap:
42,509.1 Cr.
52-wk low:
1,924.3
52-wk high:
3,516

Is Glaxosmithkline Pharmaceuticals Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Glaxosmithkline Phar: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Glaxosmithkline Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 28.8%24.4%26.6%32.5%15.8%27.7%37.7%38.1%46.5%67.6%-
Value Creation
Index
1.61.21.41.90.41.52.42.43.15.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 2,8382,9082,8713,1283,2242,9263,2783,2523,4543,7493,709
Sales YoY Gr.-2.5%-1.3%8.9%3.1%-9.3%12.1%-0.8%6.2%8.6%-
Adj EPS 22.11820.325.212.425.521.435.138.751.856.4
YoY Gr.--18.8%13.3%24.1%-50.8%105.6%-16.3%64.2%10.4%33.9%-
BVPS (₹) 128.9118.5121.4126.3107.587.3157.2102.9105.5116.1100.8
Adj Net
Profit
374304344427210432362594656878955
Cash Flow from Ops. 1392344734094915788114845821,290-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 3.1%3.1%4.6%8.6%
Adj EPS 9.9%33.1%34.4%33.9%
BVPS-1.2%1.6%-9.6%10%
Share Price 4.6% 10.6% 24.2% 8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
18.714.51720.410.626.217.52737.347.152
Op. Profit
Mgn %
16.914.417.919.420.820.523.42526.331.532.7
Net Profit
Mgn %
13.210.51213.76.514.81118.31923.425.8
Debt to
Equity
00000000000
Working Cap
Days
358573599600340136131127114104147
Cash Conv.
Cycle
19249-0713-4-13-12-3765

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Glaxosmithkline Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 56 56.4
TTM Sales (₹ Cr.) 3,691 3,709
BVPS (₹.) 100.5 100.8
Reserves (₹ Cr.) 1,533 1,538
P/BV 24.96 24.89
PE 44.82 44.50
From the Market
52 Week Low / High (₹) 1924.30 / 3515.95
All Time Low / High (₹) 20.31 / 3515.95
Market Cap (₹ Cr.) 42,509
Equity (₹ Cr.) 169.4
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Glaxosmithkline Phar:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Glaxosmithkline Phar - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Glaxosmithkline Phar

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales2,8382,9082,8713,1283,2242,9263,2783,2523,4543,749
Operating Expenses 2,3602,4892,3662,5272,5672,3272,5162,4472,5452,572
Manufacturing Costs144136137143141137148129143144
Material Costs1,3251,3981,2411,3581,3081,2571,3561,2851,3351,391
Employee Cost 443483523537629616610595624580
Other Costs 447473464489489318402439443457
Operating Profit 4784195066016575987628049091,177
Operating Profit Margin (%) 16.9%14.4%17.6%19.2%20.4%20.4%23.2%24.7%26.3%31.4%
Other Income 12373551027911176101123146
Interest 0001642221
Depreciation 25263849837968667067
Exceptional Items 2461829-341-17312-1-1445
Profit Before Tax 5785115406833064547798368161,260
Tax 202174189237213167398229226332
Profit After Tax 37633735144593287381608590928
PAT Margin (%) 13.3%11.6%12.2%14.2%2.9%9.8%11.6%18.7%17.1%24.7%
Adjusted EPS (₹)22.219.920.726.35.521.1100.036.134.854.8
Dividend Payout Ratio (%)113%75%85%76%727%142%90%89%92%99%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 2,1832,0072,0572,1401,8211,4782,6631,7431,7871,966
Share Capital 858585169169169169169169169
Reserves 2,0991,9221,9731,9701,6511,3092,4941,5741,6171,797
Minority Interest0000000000
Debt2110000000
Long Term Debt2110000000
Short Term Debt0000000000
Trade Payables328279506406357466579428625708
Others Liabilities 3,9534,3015,0755,2588451,0671,2781,0229981,293
Total Liabilities 6,4656,5887,6397,8043,0233,0124,5203,1933,4103,967

Fixed Assets

Gross Block2282994065591,452601592634663667
Accumulated Depreciation244683129696215262305343384
Net Fixed Assets 204253323430757386329329320283
CWIP 2686059231,0031201331201414
Investments 0000003665188131,118
Inventories526426500486483547535460525482
Trade Receivables127171147120100216205192222293
Cash Equivalents flag 1,3929001,2961,1711,0831,1582,4851,1561,0631,404
Others Assets 3,9494,2334,4494,593480692570517452374
Total Assets 6,4656,5887,6397,8043,0233,0124,5203,1933,4103,967

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 1392344734094905788114845821,290
PBT 5764655226546477232,4768419601,255
Adjustment -96-46-12-3113-26-1,636-40-45-68
Changes in Working Capital -124-27165-44446120-4661185
Tax Paid -206-161-202-194-180-147-112-265-254-82
Cash Flow From Investing Activity 499301-104-153-57418-4068089-46
Capex -208-258-385-243-155-421,232-43-28-22
Net Investments 565472-3352092225-1,812956-144-146
Others 14287616706235175-106181122
Cash Flow From Financing Activity -638-511-307-358-428-696-524-1,543-561-769
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -1-1-1000-0000
Interest Paid -0-0-0-1-4-4-2-1-2-1
Dividend Paid -529-424-254-296-339-677-507-1,525-542-749
Others -108-86-52-61-85-15-16-17-18-19
Net Cash Flow -02462-1026300-119-25129475

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)18.7516.0817.2621.224.7117.4218.3927.5833.4349.43
ROCE (%)28.8124.3926.5632.5415.7627.7437.7238.0646.4967.64
Asset Turnover Ratio0.590.460.420.410.621.040.950.931.151.12
PAT to CFO Conversion(x)0.370.691.350.925.272.012.130.80.991.39
Working Capital Days
Receivable Days15181916121821202023
Inventory Days58585658536055514845
Payable Days8879115123106120141143144175

Glaxosmithkline Pharmaceuticals Ltd Stock News

Glaxosmithkline Pharmaceuticals Ltd FAQs

The current trading price of Glaxosmithkline Phar on 05-Dec-2025 09:52 is ₹2,568.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Glaxosmithkline Phar stood at ₹42,509.1.
The latest P/E ratio of Glaxosmithkline Phar as of 04-Dec-2025 is 44.82.
The latest P/B ratio of Glaxosmithkline Phar as of 04-Dec-2025 is 24.96.
The 52-week high of Glaxosmithkline Phar is ₹3,516 and the 52-week low is ₹1,924.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Glaxosmithkline Phar is ₹3,691 ( Cr.) .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.

With the combined heritage of Glaxo Wellcome plc and SmithKline Beecham plc, the company has played a pivotal role in the growth of the healthcare industry for almost a century. GSK has been a leader in India since inception, with a history replete with breakthrough innovations. Through the years, it has set benchmarks in conducting business responsibly, including the ways in which it research, develop, sell, and market its products.

The company is headquartered in Mumbai with various regional and sales hubs across the country. The company has made substantial investments in one large manufacturing facility in Nashik, in the state of Maharashtra.

Business area of the company

The company is engaged in research, manufacture and make available a broad range of medicines and vaccines that benefit people. The company’s Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in anti-infectives and dermatology. Its R&D approach focuses on science related to the immune system, use of genetics and advanced technologies. Meanwhile, Its Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. The company is the leaders in India in the private segment.

Products

  • Medicines
  • Vaccines
  • Prescribing Information
  • Child-resistant packaging

Award and recognition

2017: 

  • Pharma & Medical Devices Summit & Excellence Awards 2017
  • GSK India wins the Gold Award at the TISS - CLO Summit
  • GSK India won the 'Gold award' in the Sales Enablement Category at the Tata Institute of Social Sciences (TISS) - CLO Summit in Mumbai.

2018:

  • GSK ranked among the 50 best companies in India as per People Capital Index (PCI). GSK was conferred this recognition at the HR Leadership Summit 2018.
  • GSK won the OPPI Salesforce Excellence Award 2018. The award recognises its efforts in launching and scaling an innovative, mobile based platform for sales readiness.
  • Tbact bags the Silver award for ‘Brand of the Year - Acute category 2018’ for marketing excellence. This award is a testimony to Teamwork and accountability displayed by each member of the cross functional team associated with Tbact.
  • The company has been recognised as one of the 100 Best Companies for Women by Working Mother and AVTAR. The award was received by members of the Women's Leadership Board.
  • GSK topped the Access to Medicine Index (ATMI) for the sixth time in a row. ATMI is an independent measure of the top 20 pharmaceutical companies’ efforts to improve access to healthcare in developing countries.
  • GSK's Corporate Communication and Government Affairs team was recognised by Reputation Today as the 30 Top Corporate Communication Teams in India.
  • The company has been recognised as one of the 100 Best Companies for Women by Working Mother and AVTAR for the second time in a row. This is an important milestone in its inclusion and diversity journey.
  • GSK has been recognised as the 'Best Workplaces for Women' by Great Places To Work in India. This award celebrates the efforts of the company's Women's Leadership Initiative towards creating an inclusive work environment.

2019:

  • GSK won the 2019 D&I in India Best Practices Awards in the 'Advancement of Women' category by Community Business.
  • GSK won the award for the 'Best Sales and Operations Planning Practice in Pharma' 2019.
  • T-Bact won 'Brand of the Year' award in the acute category for the second consecutive year in 2019 at the 6th AWACS Awards for marketing excellence.

2020: 

  • GSK was recognised as India’s Best Workplaces for Women 2020 by Great Places to Work
  • GSK was recognised as 100 Best Companies for Women in India 2020 by Working Mother and AVTAR

Milestones

  • 1924: Glaxo comes to India as H J Foster and Co.
  • 1947: Secondary manufacturing of pharmaceuticals begins at Glaxo’s Worli plant.
  • 1956: Primary production of vaccines begins at Worli plant.
  • 1968: Glaxo is registered as Limited company.
  • 1972: Scientists at Beecham Research laboratories discover Amoxycillin and launch Amoxil, which eventually becomes a widely used antibiotic.
  • 1981: Augmentin was launched by Beecham to combat a wide range of bacterial infections in children and adults and the antiviral Zovirax was launched by Wellcome for harpes infections.
  • 1983: Glaxo’s Nashik factory commissioned.
  • 1999: Glaxo India completes 75 years in India it is ranked ‘India’s most respective company’ by business world and again in 2003.
  • 2001: Legal merger of Glaxo India Limited and SmithKline Beecham Pharmaceuticals (India) Limited to form GlaxoSmithKline Pharmaceuticals Limited.
  • 2015: GSK acquired Novartis vaccines business (excluding influenza vaccines).
  • 2016: Launched Priorix- Tetra.
  • 2018: Launched Infanrix Hexa.
  • 2019: Launched Menveo (Quadrivalent Meningococcal Conjugate Vaccine).
  • 2019: The company has launched Spectrum, an employee resource group for raising awareness on LGBT+ among the employees.
  • 2019: Launched a development programme GSK WeLeAP - GSK Women Leadership Action Programme - to develop high potential mid-level women talent.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×